Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C88327
http://purl.obolibrary.org/obo/NCIT_C88327
Preferred Name

Bersanlimab
Definitions
A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.
prefLabel
Bersanlimab
label
Bersanlimab
NCI_META_CUI
CL413589
PDQ_Closed_Trial_Search_ID
661398
code
C88327
prefixIRI
NCIT:C88327
in_subset
Display_Name
Bersanlimab
Preferred_Name
Bersanlimab
FDA_UNII_Code
MP3N1L4OR6
Contributing_Source
CTRP
FDA
Maps_To
Anti-ICAM-1 Monoclonal Antibody BI-505
Bersanlimab
CAS_Registry
1987854-08-9
NCI_Drug_Dictionary_ID
661398
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
661398
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display